COVID-19 vaccines
The Trump administration's decision not to purchase additional doses of Pfizer's coronavirus vaccine last summer, when the option was available, has raised concerns that it may delay the delivery of a second batch of doses until the company fulfills its orders to other countries. This revelation
United States. Food and Drug Administration
The U.S. Food and Drug Administration (FDA) has approved Eisai Inc.'s receptor tyrosine kinase inhibitor LENVIMA for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). LENVIMA demonstrated a statistically significant progression-free survival (PFS) prolongation and response rate in patients with
United States. Food and Drug Administration
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's New Drug Application (NDA) for cobimetinib in combination with Zelboraf (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma.
United States. Food and Drug Administration
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's New Drug Application (NDA) for cobimetinib in combination with Zelboraf for the treatment of people with BRAF V600 mutation-positive advanced melanoma. The
Pharmaceutical industry
Eisai's US subsidiary, Eisai Inc., has received approval from the US Food and Drug Administration (FDA) for its anticancer agent Lenvima (lenvatinib mesylate) to treat locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). This marks the first country in the world where Lenvima has
United States. Food and Drug Administration
Teva Pharmaceutical Industries and Eagle Pharmaceuticals have entered into an exclusive license agreement for Eagle's bendamustine hydrochloride (HCl) rapid infusion product for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Under the agreement, Teva will be responsible for all U.S. commercial activities
Pharmaceutical industry
The U.S. Food and Drug Administration (FDA) has approved Glyxambi, a new medication combination developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, to improve glycemic control in adults with type 2 diabetes. This innovative treatment combines the dual mechanisms of a sodium glucose co-transporter-2 (SGLT2) inhibitor and
